Dalia Kamal Ewis

Dalia Kamal Ewis

Auto-generated profile, based on publicly available information

Dalia Kamal Ewis

Medical Research Group of Egypt Arlington Massachusetts USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2025 in Brain Network Disorders
Verified
Journal Article
Open access
AAAbdallah Abbas
Abdallah Abbas
HSHaneen Sabet
Haneen Sabet
MAMoaz Elsayed Abouelmagd
Moaz Elsayed Abouelmagd
MEMohamed El-Moslemani
Mohamed El-Moslemani
DEDalia Kamal Ewis
Dalia Kamal Ewis
AOAhmed Z. Obeidat
Ahmed Z. Obeidat

17 August 2026 in Brain and Behavior
Verified
Journal Article
Open access
PDF file
YHYousef Hawas
Yousef Hawas
Mohamed AbouzidMohamed Abouzid
Mohamed Abouzid
AGAhmed Farid Gadelmawla
Ahmed Farid Gadelmawla
DEDalia Kamal Ewis
Dalia Kamal Ewis
AKAbdallah Khatatbeh
Abdallah Khatatbeh
Ahmed NegidaAhmed Negida
Ahmed Negida
Background: Tirzepatide (TZP), the first approved dual glucagon‐like peptide 1 (GLP‐1)/glucose‐dependent insulinotropic polypeptide (GIP) agonist, has shown neuroprotective effects in preclinical models and early observational studies. This review maps and appraises current preclinical and clinical evidence on TZP's potential neuroprotective effects in neurodegenerative diseases (Alzheimer's and Parkinson's disease), neuroinflammation, cerebrovascular outcomes, neurovestibular disorders, brain tumor response, and idiopathic intracranial hypertension. Methods: PubMed, Scopus, Web of Science, Embase, and Elton B. Stephens Company (EBSCO) were searched through September 30, 2025. Eligible sources included original preclinical or clinical studies reporting neurological or neuroprotective effects of TZP. Quality was assessed using SYstematic Review Centre for Laboratory animal Experimentation (SYRCLE) and Collaborative Approach to Meta‐Analysis and Review of Animal Data from Experimental Studies (CAMARADE) for in vivo studies, toxicological data reliability assessment tool (ToxRTool) for in vitro, Newcastle‐Ottawa scale (NOS) for cohorts, and Joanna Briggs Institute (JBI) for case reports. Results: Twenty‐two studies met inclusion criteria as follows: 11 preclinical investigations, 3 retrospective cohorts, and 8 case reports. Preclinical studies demonstrated mitochondrial stabilization (adenosine triphosphate [ATP] restoration; PINK1/Parkin), anti‐oxidative and anti‐inflammatory signaling, synaptic support (PSD‐95/synaptophysin), and blood–brain barrier reinforcement (claudin‐1), alongside behavioral improvements. Retrospective cohorts reported reduced cerebrovascular and neurodegenerative disease incidence, papilledema, and headaches, though one cohort identified higher risk of central vertigo and vestibular neuronitis. Case reports documented compression neuropathies, autoimmune encephalitis, hypoglycemia‐related seizures, psychiatric reactions, and rhabdomyolysis, most resolving with dose adjustment or discontinuation. Risk‐of‐bias appraisal revealed frequent “unclear” ratings in animal studies, “reliable with restrictions” in vitro, and high NOS scores for cohorts. Conclusions: TZP exhibits biologically plausible neuroprotective mechanisms preclinically. Prospective trials with standardized neurological endpoints, active‐comparator designs, and structured safety monitoring are warranted.

20 November 2025 in Brain Network Disorders
Verified
Journal Article
Open access
HSHaneen Sabet
Haneen Sabet
SRShrouk Ramadan
Shrouk Ramadan
DEDalia Kamal Ewis
Dalia Kamal Ewis
MZMohamed Ahmed Zanaty
Mohamed Ahmed Zanaty
MEMohamed El-Moslemani
Mohamed El-Moslemani
AAAbdallah Abbas
Abdallah Abbas

5 August 2026 in Disability and Rehabilitation
Verified
Journal Article
Closed access
YHYousef Hawas
Yousef Hawas
AAAhmed Abdelmageed
Ahmed Abdelmageed
Mohamed AbouzidMohamed Abouzid
Mohamed Abouzid
AHAbdullah Ashraf Hamad
Abdullah Ashraf Hamad
MEMohamed El-Moslemani
Mohamed El-Moslemani
ARAmanda Cyntia Lima Fonseca Rodrigues
Amanda Cyntia Lima Fonseca Rodrigues
Multiple sclerosis (MS) is an autoimmune-mediated disorder of the central nervous system (CNS) where inflammation, demyelination, and neurodegeneration occur [1]. It is considered the most common n...

13 November 2026 in The Journal of Headache and Pain
Verified
Journal Article
Open access
ASAhmed Amir Samir
Ahmed Amir Samir
Mona NadaMona Nada
Mona Nada
AEAhmed Hussein Elamir
Ahmed Hussein Elamir
AAAyoub Ali Alshaikh
Ayoub Ali Alshaikh
EMElsayed S. Moubarak
Elsayed S. Moubarak
Ramy Mohamed GhazyRamy Mohamed Ghazy
Ramy Mohamed Ghazy